Thomas Weisel Initiates Coverage on Idenix Pharmaceuticals (IDIX) with an Overweight
More News related to IDIX
- Idenix Pharmaceuticals Initiates Phase II Clinical Trial of IDX184 in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
- Caris & Co Downgrades Idenix Pharmaceuticals (IDIX) to Above Average
- Morning Movers 10/30: PVFC, WPTE, CNXT, HPOL, TVL, MSTR Higher; NVTL, GFIG, TSRA, GGC, IDIX Lower
- Idenix (IDIX) Announces Presentations of IDx184 at AASLD in Boston
- Idenix Pharmaceuticals Presents Data on IDX184 for the Treatment of Hepatitis C Virus (HCV)
Thomas Weisel initiates coverage on Idenix Pharmaceuticals (Nasdaq: IDIX) with an Overweight rating. Price target $8.
To see more analyst ratings on IDIX Click Here.
Idenix Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and Europe.
Related Categories
New CoverageStocks Mentioned
-0.04Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
